Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Japan Tobacco
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 15, 2020
Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.